• SELECT SITE CURRENCY
Select a currency for use throughout the site
DRG Insights: Benign Prostate Hyperplasia (G7)
Decision Resources, Inc, May 2012, Pages: 53
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives.
Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) affect 159 million men aged 40 or older in the major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Demographic trends suggest an increase in the prevalent LUTS and BPH populations as a result of aging populations in the markets under study.
Therapies for LUTS and BPH are very effective, but opportunity remains for therapies that can increase patient adherence to medications. Also, BPH is a progressive disease, and new therapies are needed that can stop disease progression and prevent surgery.
Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Unmet Needs Emerging Therapies
Important Endpoints in Prescribing Decisions
2010 and 2010 sales and Market Share